|
Oct 10
|
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
|
|
Oct 9
|
Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Oct 7
|
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
|
|
Sep 5
|
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
|
|
Sep 2
|
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
|
|
Aug 26
|
Here's Why You Should Consider Buying Akebia (AKBA) Stock
|
|
Aug 2
|
Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights
|
|
Jul 29
|
Akebia Therapeutics to Present at Upcoming Investor Conferences
|
|
Jun 24
|
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
|
|
Jun 21
|
Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
|
|
May 14
|
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
|
|
May 11
|
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
|
|
May 10
|
Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
|
|
May 10
|
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
|
|
May 9
|
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 9
|
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 2
|
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
|
|
Apr 28
|
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
|
|
Mar 28
|
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
|